Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Greig

Showing results (1-10 of 332) with videos related to

Pageof 34
Sort By:
Trends in Pharmacological Sciences|July 23, 2003
The glucagon-like peptides: a double-edged therapeutic sword?TracyAnn Perry, Nigel H Greig
Current Alzheimer Research|June 25, 2005
Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's diseaseTracyann Perry, Nigel H Greig
Journal of Alzheimer'S Disease : JAD|January 8, 2003
The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's diseaseTracyAnn Perry, Nigel H Greig
Current Alzheimer Research|December 12, 2012
Was phenserine a failure or were investigators mislead by methods?Robert E Becker, Nigel H Greig
CNS & Neurological Disorders Drug Targets|January 9, 2009
Alzheimer's disease drug development: old problems require new prioritiesRobert E Becker, Nigel H Greig
Current Pharmaceutical Design|July 14, 2017
Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse DiseasesMohammad A Kamal, Nigel H Greig
Expert Opinion on Drug Discovery|March 24, 2012
Increasing the success rate for Alzheimer's disease drug discovery and developmentRobert E Becker, Nigel H Greig
Neurobiology of Aging|June 3, 2004
Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's diseaseDebomoy K Lahiri, Nigel H Greig
Current Alzheimer Research|October 19, 2017
Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological PerspectivesMohammad A Kamal, Nigel H Greig
Current Alzheimer Research|August 12, 2008
Alzheimer's disease drug development in 2008 and beyond: problems and opportunitiesRobert E Becker, Nigel H Greig
Pageof 34

Showing results (1-10 of 332) with videos related to

Sort By:
Pageof 34
Trends in Pharmacological Sciences|July 23, 2003
The glucagon-like peptides: a double-edged therapeutic sword?TracyAnn Perry, Nigel H Greig
Current Alzheimer Research|June 25, 2005
Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's diseaseTracyann Perry, Nigel H Greig
Journal of Alzheimer'S Disease : JAD|January 8, 2003
The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's diseaseTracyAnn Perry, Nigel H Greig
Current Alzheimer Research|December 12, 2012
Was phenserine a failure or were investigators mislead by methods?Robert E Becker, Nigel H Greig
CNS & Neurological Disorders Drug Targets|January 9, 2009
Alzheimer's disease drug development: old problems require new prioritiesRobert E Becker, Nigel H Greig
Current Pharmaceutical Design|July 14, 2017
Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse DiseasesMohammad A Kamal, Nigel H Greig
Expert Opinion on Drug Discovery|March 24, 2012
Increasing the success rate for Alzheimer's disease drug discovery and developmentRobert E Becker, Nigel H Greig
Neurobiology of Aging|June 3, 2004
Lethal weapon: amyloid beta-peptide, role in the oxidative stress and neurodegeneration of Alzheimer's diseaseDebomoy K Lahiri, Nigel H Greig
Current Alzheimer Research|October 19, 2017
Editorial: Alzheimer's Disease: From Molecular Mechanisms to Psychobiological PerspectivesMohammad A Kamal, Nigel H Greig
Current Alzheimer Research|August 12, 2008
Alzheimer's disease drug development in 2008 and beyond: problems and opportunitiesRobert E Becker, Nigel H Greig
Pageof 34